3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neuroblastoma
3
Triple Negative Breast Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Ganglioneuroblastoma
2
Transplant-Related Hematologic Malignancy
1
Recurrence
1
Prostatic Neoplasms
1
Neoplasms
1
Multiple Myeloma
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma
1
Locally Advanced Pancreatic Adenocarcinoma
1
Leukemia, Plasma Cell
1
Leukemia
1
Hodgkin Disease
1
Gliosarcoma
1
Glioblastoma
1
Carcinoma, Non-Small-Cell Lung
1
Adenoma, Islet Cell
1
Interventions
Magnetic Resonance Spectroscopy
9
Specimen Handling
5
Nivolumab
5
selpercatinib
4
Iodine-124
4
Biopsy
4
binimetinib
3
Iodine-131
3
Cetuximab
3
ulixertinib
2
trametinib
2
pembrolizumab
2
omipalisib
2
larotrectinib
2
defactinib
2
dabrafenib
2
Surveys and Questionnaires
2
Sunitinib
2
Radiosurgery
2
Ipilimumab
2
Immunoglobulin G
2
Gemcitabine
2
Disulfides
2
Cyclophosphamide
2
CTLA-4 Antigen
2
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
tipifarnib
1
temsirolimus
1
sapanisertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
sargramostim
×
90 days
×
Clear all
No trials found.